Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VR-FND for Relapsed or Refractory Follicular Lymphoma
NCT00510887Phase 2Terminated
- Sponsor
- Duke University
- Start
- Jan 2007
- Primary completion
- Nov 2012
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in follicular lymphoma (FL), sponsored by Duke University. Started Jan 2007; status: terminated.
02
Drugs
bortezomib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00510887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00510887.